- Home
- LENZ vs ORIC Comparison
LENZ vs ORIC Comparison
Compare LENZ & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- ORIC
- Stock Information
- Founded
- LENZ 2019
- ORIC 2014
- Country
- LENZ United States
- ORIC United States
- Employees
- LENZ N/A
- ORIC N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- ORIC Health Care
- Exchange
- LENZ Nasdaq
- ORIC Nasdaq
- Market Cap
- LENZ 1.2B
- ORIC 1.1B
- IPO Year
- LENZ 2021
- ORIC 2020
- Fundamental
- Price
- LENZ $31.84
- ORIC $12.97
- Analyst Decision
- LENZ Strong Buy
- ORIC Strong Buy
- Analyst Count
- LENZ 4
- ORIC 8
- Target Price
- LENZ $56.25
- ORIC $16.57
- AVG Volume (30 Days)
- LENZ 1.2M
- ORIC 1.5M
- Earning Date
- LENZ 11-05-2025
- ORIC 11-11-2025
- Dividend Yield
- LENZ N/A
- ORIC N/A
- EPS Growth
- LENZ N/A
- ORIC N/A
- EPS
- LENZ N/A
- ORIC N/A
- Revenue
- LENZ $5,000,000.00
- ORIC N/A
- Revenue This Year
- LENZ N/A
- ORIC N/A
- Revenue Next Year
- LENZ $285.82
- ORIC N/A
- P/E Ratio
- LENZ N/A
- ORIC N/A
- Revenue Growth
- LENZ N/A
- ORIC N/A
- 52 Week Low
- LENZ $16.54
- ORIC $3.90
- 52 Week High
- LENZ $50.40
- ORIC $14.93
- Technical
- Relative Strength Index (RSI)
- LENZ 33.24
- ORIC 55.15
- Support Level
- LENZ $30.66
- ORIC $11.71
- Resistance Level
- LENZ $42.98
- ORIC $14.17
- Average True Range (ATR)
- LENZ 3.10
- ORIC 0.75
- MACD
- LENZ -1.51
- ORIC -0.20
- Stochastic Oscillator
- LENZ 7.69
- ORIC 40.06
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.